Complications of Guillain-Barré syndrome

References

• van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–482.
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain-Barré syndrome. Expert Rev Clin Immunol. 2013;9:627–639.
   PubMed Web of Science ®Google Scholar
• Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–720.
   PubMed Web of Science ®Google Scholar
• Govoni V, Granieri E, Manconi M, et al. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy. J Neurol Sci. 2003;216:99–103.
   PubMed Web of Science ®Google Scholar
• Gensicke H, Datta AN, Dill P, et al. Increased incidence of Guillain-Barré syndrome after surgery. Eur J Neurol. 2012;19:1239–1244.
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Yuki N. Surgery itself does not trigger Guillain-Barré syndrome. Eur J Neurol. 2013;20:e40.
   PubMed Web of Science ®Google Scholar
• Wu X, Wu W, Wang Z, et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China. PLoS One. 2014;9:e104074.
   PubMed Web of Science ®Google Scholar
• McGrogan A, Madle GC, Seaman HE, et al. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150–163.
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–133.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Zheng XY, Zhu J. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev. 2013;24:443–453.
   PubMed Web of Science ®Google Scholar
• Sheikh KA, Zhang G, Gong Y, et al. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann Neurol. 2004;56:228–239.
   PubMed Web of Science ®Google Scholar
• Tatsumoto M, Koga M, Gilbert M, et al. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a. J Neuroimmunol. 2006;177:201–208.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol. 1999;100:74–97.
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–679.
   PubMed Web of Science ®Google Scholar
• Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry. 2012;83:23–28.
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Wermuth P, Hartung HP, et al. Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol. 1997;42:171–179.
   PubMed Web of Science ®Google Scholar
• Mukerji S, Aloka F, Farooq MU, et al. Cardivascular complications of the Guillain-Barré syndrome. Am J Cardiol. 2009;104:1452–1455.
   PubMed Web of Science ®Google Scholar
• Patel MB, Goyal SK, Punnam SR, et al. Guillain-Barré syndrome with asystole requiring permanent pacemaker: a case report. J Med Case Rep. 2009;3:5.
   PubMedGoogle Scholar
• Zhang Q, Gu Z, Jiang J, et al. Orthostatic hypotension as a presenting symptom of the Guillain-Barré syndrome. Clin Auton Res. 2010;20:209–210.
   PubMed Web of Science ®Google Scholar
• Gunatilake SS, Wimalaratna H. Guillain-Barré syndrome presenting with Raynaud’s phenomenon: a case report. BMC Neurol. 2014;14:174.
   PubMed Web of Science ®Google Scholar
• Mishra A, Dave N, Mehta M. Fulminant Guillain-Barré syndrome with myocarditis. J Family Med Prim Care. 2014;3:84–85.
   PubMedGoogle Scholar
• Monzón Vázquez T, Florit E, Marqués Vidas M, et al., et al. Syndrome of inappropriate antidiuretic hormone hypersecretion. Nefrologia. 2011;31:498–499.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, McMeniman J, Cabela R, et al. SIADH and dysautonomia as the initial presentation of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2012;83:344–345.
   PubMed Web of Science ®Google Scholar
• Ramanathan M. Hyponatraemic encephalopathy as the initial presentation of Guillain-Barré syndrome. Med J Malaysia. 2008;63:426–427.
   PubMedGoogle Scholar
• Saifudheen K, Jose J, Gafoor VA, et al. Guillain-Barre syndrome and SIADH. Neurology. 2011;76:701–704.
   PubMed Web of Science ®Google Scholar
• Saroja AO, Naik KR, Khanpet MS. Uncommon dyselectrolytemia complicating Guillain-Barré syndrome. J Neurosci Rural Pract. 2013;4:328–330.
   PubMedGoogle Scholar
• Chen A, Kim J, Henderson G, et al. Posterior reversible encephalopathy syndrome in Guillain-Barré syndrome. J Clin Neurosci. 2015;22:914–916.
   PubMed Web of Science ®Google Scholar
• Bavikatte G, Gaber T, Eshiett MU. Posterior reversible encephalopathy syndrome as a complication of Guillain-Barré syndrome. J Clin Neurosci. 2010;17:924–926.
   PubMed Web of Science ®Google Scholar
• Wei DY, Kao J, Wu TY, et al. Reversible cerebral vasoconstriction in Guillain-Barré syndrome. J Clin Neurosci. 2015;13:S0967-5868(15)00059-4.
   Google Scholar
• Cruto CA, Pinta NC, Pato MV. Reversible focal encephalic abnormalities in a patient with Guillain-Barré syndrome. Arg Neuropsiquiatr. 2012;70:471–472.
   PubMed Web of Science ®Google Scholar
• Mapstone R, Clark CV. The prevalence of autonomic neuropathy in glaucoma. Trans Ophthalmol Soc UK. 1985;104:265–269.
   PubMedGoogle Scholar
• Baxter JM, Alexander P, Maharajan VS. Bilateral, acute angle-closure glaucoma associated with Guillain-Barre syndrome variant. BMJ Case Rep. 2010;2010:bcr1120092487.
   PubMedGoogle Scholar
• Man BL, Fu YP. Intestinal pseudo-obstruction as a presentation symptom of Guillain-Barré syndrome. BMJ Case Rep. 2014;2014:bcr2014205255.
   Google Scholar
• Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic plasma exchange: 2013 Update. J Clin Apher. 2014;29:211–219.
   PubMed Web of Science ®Google Scholar
• Lin JH, Tu KH, Chang CH, et al. Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome. Transfus Apher Sci. 2015;52:78–83.
   PubMed Web of Science ®Google Scholar
• Koichihara R, Hamano S, Yamashita S, et al. Posterior reversible encephalopathy syndrome associated with IVIG in a patient with Guillain-Barré syndrome. Pediatr Neurol. 2008;39:123–125.
   PubMed Web of Science ®Google Scholar
• Byrne NP, Henry JC, Herrmann DN, et al. Neuropathologic findings in Guillain-Barré patient with stroke after IVIg therapy. Neurology. 2002;59:458–461.
   PubMed Web of Science ®Google Scholar
• Stetefeld HR, Lehmann HC, Fink GR, et al. Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher Syndrome/Bickerstaff Brain Stem Encephalitis Overlap Syndrome. J Stroke Cerebrovasc Dis. 2014;23:e423–5.
   PubMed Web of Science ®Google Scholar
• Doss-Esper CE, Singhal AB, Smith MS, et al. Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in Guillain-Barré syndrome. J Neuroimag. 2005;15:188–192.
   PubMed Web of Science ®Google Scholar
• De Havenon A, Davis G, Hoesch R. Splenic rupture associated with primary CMV infection, AMSAN, and IVIG. J Neuroimmunol. 2014;272:103–105.
   PubMed Web of Science ®Google Scholar
• Nguyen TP, Biliciler S, Wahed A, et al. Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg. Neurol Neuroimmunol Neuroinflamm. 2014;1:e50.
   PubMedGoogle Scholar
• Rhee DY, Park GH, Chang SE, et al. Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain-Barré syndrome. J Eur Acad Dermatol Venereol. 2009;23:602–604.
   Google Scholar
• Moghadan-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49:239–248.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2012;8:CD001446.
   PubMed Web of Science ®Google Scholar
• Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67:781–787.
   PubMed Web of Science ®Google Scholar
• Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006;5:1021–1028.
   PubMed Web of Science ®Google Scholar
• Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. Neurology. 2000;54:2311–2315.
   PubMed Web of Science ®Google Scholar
• Ali MI, Fernández-Pérez ER, Pendem S, et al. Mechanical ventilation in patients with Guillain-Barré syndrome. Respir Care. 2006;51:1403–1407.
   PubMed Web of Science ®Google Scholar
• Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit. J Neurol Sci. 2008;264:121–128.
   PubMed Web of Science ®Google Scholar
• Le Guennec L, Brisset M, Viala K, et al. Post-traumatic stress symptoms in Guillain-Barré syndrome patients after prolonged mechanical ventilation in ICU: a preliminary report. J Peripher Nerv Syst. 2014;19:218–223.
   PubMed Web of Science ®Google Scholar
• Filippone EJ, Kanzaria M, Bell R, et al. Secondary membranous nephropathy associated with Guillain-Barré syndrome. Case Rep Nephrol Urol. 2013;3:34–39.
   PubMedGoogle Scholar
• Rodríguez-Iturbe B, García R, Rubio L, et al. Acute glomerulonephritis in the Guillain-Barré-Strohl syndrome. Report of nine cases. Ann Intern Med. 1973;78:391–395.
   PubMed Web of Science ®Google Scholar
• Tojo K, Nitta K, Ishii W, et al. A young man with anti-NMDAR encephalitis following Guillain-Barré syndrome. Case Rep Neurol. 2011;3:7–13.
   PubMedGoogle Scholar
• Amrish S, Vineeta S, Nitin V. Guillain-Barre syndrome complicated by acute fatal rhabdomyolysis. Indian J Crit Care Med. 2014;18:241–243.
   PubMedGoogle Scholar
• Karkare K, Sinha S, Taly AB, et al. Prevalence and profile of sleep disturbances in Guillain-Barre syndrome: a prospective questionnaire-based study during 10 days of hospitalization. Acta Neurol Scand. 2013;127:116–123.
   PubMed Web of Science ®Google Scholar
• Marin LF, Dos Santos WA, Pedroso JL, et al. Restless legs syndrome associated with Guillain-Barré syndrome: a report of two cases. Parkinsonism Relat Disord. 2010;16:418–419.
   PubMed Web of Science ®Google Scholar
• Ruts L, Drenthen J, Jongen JL, et al. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology. 2010;75:1439–1447.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochran Database Syst Rev. 2015;4:CD009950.
   PubMedGoogle Scholar
• Sharshar T, Polito A, Porcher R, et al. Relevance of anxiety in clinical practice of Guillain-Barré syndrome: a cohort study. BMJ Open. 2012;2:e2000893.
   Web of Science ®Google Scholar
• Cochen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndrome. Brain. 2005;128:2535–2545.
   PubMed Web of Science ®Google Scholar
• Drory VE, Bronipolsky T, Bluvshtein V, et al. Occurrence of fatigue over 20 years after recovery form Guillain-Barré syndrome. J Neurol Sci. 2012;316:72–75.
   PubMed Web of Science ®Google Scholar
• Rekand T, Gramstad A, Vedeler CA. Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis. J Neurol. 2009;256:349–354.
   PubMed Web of Science ®Google Scholar
• Kuitwaard K, Van Koningsveld R, Ruts L, et al. Recurrent Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2009;80:56–59.
   PubMed Web of Science ®Google Scholar
• Sung JY, Tani J, Park SB, et al. Early identification of ‘acute-onset’ chronic inflammatory demyelinating polyneuropathy. Brain. 2014;137:2155–2163.
   PubMed Web of Science ®Google Scholar
• Bernsen RA, De Jager AE, Kuijer W, et al. Psychosocial dysfunction in the first year after Guillain-Barré syndrome. Muscle Nerve. 2010;41:533–539.
   PubMed Web of Science ®Google Scholar
• Jameson R, Garreau De Loubresse C, et al Spinal neuroarthropathy associated with Guillain-Barré syndrome. Eur Spine J. 2010;19:S108–13.
   PubMed Web of Science ®Google Scholar
• Ohnmar H, Roohi SA, Naicker AS. Massive heterotopic ossification in Guillain-Barré syndrome: a rare case report. Clin Ter. 2010;161:529–532.
   PubMed Web of Science ®Google Scholar
• Edwards MR, Panteliadis P, Lucas JD. Neuromuscular scoliosis as a sequelae of Guillain-Barré syndrome. J Pediatr Orthop B. 2010;19:95–97.
   PubMed Web of Science ®Google Scholar
• Myers KA, Baker SK. Late-onset seropositive Isaacs’ syndrome after Guillain-Barré syndrome. Neuromuscul Disord. 2009;19:288–290.
   PubMed Web of Science ®Google Scholar